Obermatt
See Similar Stocks →

Flags

Financial distress

Ultragenyx Pharmaceutical

NSQ:RARE · US90400D1081
BiotechnologyMedium

360

24
Profit price25
Cash yield1
Price/Sales91
Price/Book84
Return on Capital21
Cash Return on Capital10
EBIT Margin32
Gross Profitability27
Accruals65
Owner Earnings Margin46
Sales growth56
Profit Growth29
Long-Term EPS Growth62
Reinvestment33
Price momentum8
Debt load5
Refinancing77
Debt Payback1
Liquidity62
Analyst ratings18
Opinion Changes26
Price Target Upside84
Market mood40
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Ultragenyx Pharmaceutical doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2010
Employees1,471
Websiteultragenyx.com
ISINUS90400D1081
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsHealth DiagnosticsOsteoporosisOncologyGenetic DisorderCentral Nervous SystemBiotechnologyHealth CarePharmaceutical

Description

Ultragenyx Pharmaceutical Inc. operates as a biopharmaceutical company. The company is committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of ap…

Analysis

Middle-of-the-road

Ultragenyx Pharmaceutical Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
59
2026

All-time high

59

Jun 2026

All-time low

25

Mar 2026

Average rank

42

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
91
—
—
—
Price/Earnings
86
—
—
—
Price/Book
84
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
100
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ultragenyx Pharmaceutical with its peers
ArriVent BioPharma
NMQ:AVBP
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Regenxbio
NSQ:RGNX
17
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Abeona Therapeutics
NAQ:ABEO
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sagimet Biosciences
NMQ:SGMT
59
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Benitec Biopharma
NAQ:BNTC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
CytomX Therapeutics
NSQ:CTMX
8
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →